PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC12972984::ACT039560

MAVP

Evidence text

Paper-level observation

Both MAVP and VAN treatment groups demonstrated significant attenuation of ROS production compared to vehicle (PBS) controls, with MAVP exhibiting superior efficacy in reducing both ROS+ cell population (Fig. 1J) and mean fluorescence intensity (Fig. 1K).
textConfidence: medium

Assay observation

Activity
Antioxidant
Subtype
Antibacterial
Measure
percent_inhibition
Comparator
=
Raw observation
significant attenuation of ROS production; superior efficacy in reducing ROS+ cell population and mean fluorescence intensity
Normalized measurement
Not reported by source
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
HUVEC
Assay method
Not reported by source
Sequence
MAGGGATWLPPR
Standardization
ready simple

Source publication

Targeting VEGFR2 inhibition within a spatially-confined conduit promotes nerve self-resolution and alleviates mechanical allodynia

Bioactive Materials · 2026

DOI 10.1016/j.bioactmat.2026.03.009 PMC12972984
Parent mention

Related peptide identities

PEPDIA-PLP-001965

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.